Gouri 1x1ml
Important Notice
Regulated medical device (EU MDR 2017/745). For sale exclusively to qualified healthcare professionals.
What this purchase includes
- Original productFrom the manufacturer or an official distributor, CE marked.
- Batch and expiry documentedRecorded per unit on the delivery note and the invoice.
- Controlled storageOur own Madrid warehouse, 12 to 18 °C under 24 h control.
- Dispatch in 24 to 48 hFrom Madrid, insured and with a tracking number.
- Reachable Monday to Friday9:00 to 17:00 by WhatsApp and email. People, not forms.
GOURI® from Dexlevo (South Korea) is the first injectable polycaprolactone (PCL) biostimulator in fully liquid form, without microspheres or suspended particles. This absence of particles is its defining feature: the product distributes itself within the tissue plane, allows the use of very fine needles and requires no subsequent manual moulding. It is applied using a scheme of points distributed across the whole face for global biostimulation, rather than as a localised volumising filler.
- Active ingredient liquid PCL 21 %
- Format particle-free
- Contents 1 syringe × 1.0 ml
- Needle 30G–35G
- Plane deep dermis / subdermal
Composition and technology
- Polycaprolactone (PCL) at 21 %, in liquid, solubilised form.
- CESABP technology (Collagen Enabled Solubilized Active and Biodegradable Polymer): Dexlevo's patented technology, which makes it possible to present the polymer in liquid, solubilised form instead of as microspheres suspended in a gel.
- Mechanism: the polymer induces neocollagenesis in the tissue in which it is deposited. As it is not particulate, it distributes diffusely throughout the injection plane rather than concentrating in discrete deposits, which underpins the manufacturer's global rejuvenation approach.
- Biodegradation: PCL is degraded by hydrolysis; the manufacturer places the polymer degradation period at between 6 and 12 months.
Important note: GOURI is not a poly-L-lactic acid (PLLA) product. Its active ingredient is polycaprolactone (PCL), a different polymer, and its formulation is liquid, without the microspheres characteristic of PLLA biostimulators. It also requires no reconstitution or prior hydration time.
Indications and treatment areas
Injectable biostimulator indicated for global facial rejuvenation in adult patients.
- Moderate to marked signs of facial ageing
- Loss of skin firmness and elasticity
- Diffuse skin laxity
- Global improvement of facial skin quality
The manufacturer states that clinical data for other areas — neck and dorsum of the hands — are still being collected, and these areas are therefore not presented here as an established indication.
Technique and treatment protocol
- No reconstitution: the product is supplied ready to use in a pre-filled syringe. It requires no dilution or prior standing time.
- Injection plane: deep dermis or subdermal plane.
- Needle: 30G to 35G. The absence of particles is what allows such fine gauges to be used; it may also be applied by cannula according to operator preference.
- Application scheme: the manufacturer's protocol distributes the product across defined anatomical points per hemiface — frontal region, medial cheek, lateral cheek, perioral region and periocular region — up to a total of 10 points on the whole face, in order to achieve homogeneous distribution.
- No subsequent moulding: being a non-particulate liquid formulation, it requires no shaping massage after injection.
- Number of sessions: the manufacturer states that one session is sufficient in most cases, with the option of 1 or 2 additional sessions 4 to 6 weeks apart in more severe cases.
- Onset of result: first visible changes in 1 to 2 weeks, with progressive improvement through neocollagenesis.
The manufacturer does not publish a fixed volume per injection point; the figures circulating in distribution documentation are inconsistent and are therefore not reproduced here. Take the dosage from the instructions for use accompanying the product.
Technical data
| Manufacturer | Dexlevo Inc. — South Korea |
|---|---|
| Active ingredient | Liquid polycaprolactone (PCL) at 21 % |
| Form | Solubilised liquid solution, without microspheres or particles |
| Technology | CESABP |
| Presentation | 1 pre-filled syringe of 1.0 ml |
| Needle | 30G–35G (alternatively cannula) |
| Injection plane | Deep dermis / subdermal |
| Reconstitution | Not required |
| Polymer degradation | 6–12 months according to the manufacturer |
| Classification | CE-marked medical device. Manufactured under ISO 13485 |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: store in the original packaging under the temperature conditions stated on it, protected from direct sunlight. Do not freeze.
- Do not use after the expiry date stated on the packaging.
- Sterile single-use product. Do not reuse or re-sterilise.
- The pack includes: 1 pre-filled syringe of 1.0 ml, needles and instructions for use.
Contraindications and warnings
Contraindications: known hypersensitivity to polycaprolactone or to any of the components of the formulation; active skin infection or inflammation in the treatment area; pregnancy and breastfeeding; active autoimmune disease; tendency to hypertrophic or keloid scarring; patients under 18 years of age.
Caution: do not apply in areas with pre-existing permanent implants. Do not combine in the same session with ablative laser, deep peeling or dermabrasion. Assess individually in patients on anticoagulant or antiplatelet therapy.
Never inject intravascularly. Observe the stated injection plane. Always consult the instructions for use enclosed in the packaging before application.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the official documentation of the manufacturer Dexlevo and its distribution. This data sheet does not replace the instructions for use accompanying the product.